- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04192123
Open-Label Test of the HM242 Medical Devices to Evaluate Safety and Local Tolerability
A Prospective, Monocentric, Open-Label Test of the HM242 Wound and Irrigation Solution and Gel on Healthy Skin to Evaluate Safety and Local Tolerability
It is the first clinical study aimed at assessing the safety and tolerability of HM242-Solution and HM242-Gel after their application under occlusion on intact skin. The HM242-Solution is intended for chronic wounds (e.g. pressure, venous leg and diabetic foot ulcers). The HM242-Solution should be used for physical rinsing and cleansing and subsequent decolonization of the wound prior to treatment with hydrogels and dressings. The HM242-Gel is a hydrogel for wound bed preparation to support the healing of the skin due to cleansing, moistening and subsequent decolonization and the coating of the wound.
The study will be conducted in outpatient manner, adult patients who are healthy and has an intact skin.
This is an prospective, open label, monocentric study. No comparative control group is planned as no other preventing infection solution is commercially available at this time.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hamburg, Germany, 22609
- Dermatologische Praxis Prager & Partner
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Generally healthy male or female subjects aged ≥ 18 years and ≤ 65 years.
- Healthy skin on the upper arms
- Skin type visually assessed from pale white to light brown
- Females with childbearing potential must have a negative urine pregnancy test at baseline and must agree to use a highly effective method of contraception for the duration of the clinical investigation.
- Provide a personally signed and dated informed consent indicating that the subject has been informed of all pertinent aspects of the trial prior to any trial-related activity and that all information has been understood
Exclusion Criteria:
- Breastfeeding or pregnant women
- Extremely tanned skin that may interfere with the tolerability assessment based on Investigator judgment
- Subjects with known or suspected allergies or skin hypersensitivity (e.g. acute dermatitis)
- Subjects with known or suspected allergies or hypersensitivity to any of the components of the Investigational Medical Devices
- Any illness or circumstance that could affect the trial purpose in the opinion of the investigator (e.g. intensive UV exposure)
- Dermatologic diseases or skin conditions (e.g. tattoos, multiple birth marks in the test area) that might interfere with the evaluation of test site reaction
- Within 3 weeks prior to Day 1 and during the entire trial: Any systemic or topical medication or therapy likely to interfere with the trial purposes: e.g. immune-modulating or immunosuppressive therapy (e.g. corticosteroids, cytotoxics, cyclosporine or radiotherapy).
- Within 7 days prior to Day 1 and during the entire trial: any topical dermatological agents applied on the upper arms (drugs or medical device), except usual skin care preparations and skin cleansing preparations like anionic tensides, cleansing soaps ointments, oils, enzymes, etc. (not allowed on test areas during the trial)
- During the entire trial: exposure to sunlight that could lead to sunburns or photo sensibilization reactions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
All patients will receive an occlusive patch per test treatment as follows:
|
HM242-Solution and HM242-Gel will be topically applied in an occlusive patch for 48h on healthy skin on the subject's outer part of the upper arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of related Adverse Events from Study Start until the End of Study (EoS)
Time Frame: Day 1 to Day 10
|
to assess safety of HM242-Solution and HM242-Gel in healthy subjects which will be assessed in terms of related adverse events occurrence during the study (as reported by subjects and/or observed by the investigator)
|
Day 1 to Day 10
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post treatment assessment (via patch test scoring system provided by International Contact Dermatitis Research Group) by the Investigator. Scoring system: "-" no reaction; "Ir" irritative reaction (vesicles, blister, necrosis)
Time Frame: Day 3, Day 4, Day 5
|
to assess local tolerability of HM242-Solution and HM242-Gel in healthy subjects which will be assessed by the investigator using the patch test
|
Day 3, Day 4, Day 5
|
Collaborators and Investigators
Investigators
- Principal Investigator: Welf Prager, Dr. med, Dermatologische Praxis Prager & Partner
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- OPM-G-H-1902
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intact Skin
-
University Hospital Schleswig-HolsteinCompletedIntact Scaphoid Bone | Intact Metacarpal Bone | Fractured Scaphoid Bone | Fractured Metacarpal BoneGermany
-
University Hospital Schleswig-HolsteinCompletedIntact Scaphoid Bone | Intact Metacarpal Bone | Fractured Scaphoid Bone | Fractured Metacarpal BoneGermany
-
Association of Dutch Burn CentresEindhoven University of TechnologyCompletedIntact Skin | Contaminant Given to PatientNetherlands
-
Smith & Nephew Orthopaedics AGTerminatedPrimary Osteoarthritis | Secondary Osteoarthritis | Dysplasia Osteoarthritis | Avascular Femoral Neck Necrosis | Post-Traumatic Femoral Neck Necrosis | Intact Femoral Neck With Good Bone QualityNetherlands, Germany, Poland
-
Sara VareaCompletedPreterm Labor With Intact MembranesSpain
-
Vastra Gotaland RegionNot yet recruitingPulmonary Atresia With Intact Ventricular Septum
-
PharmanexCompletedSkin Elasticity | Beauty Drink Powder | Cosmetic Apparatus on Skin | Skin Dryness | Skin Moisture | Skin Evenness | Skin FirmnessChina
-
West Virginia UniversityMary Babb Randolph Cancer Center at West Virginia University Hospitals; West...RecruitingSkin Cancer | Skin Lesion | Skin Melanoma | Tumor SkinUnited States
-
Medical University of ViennaUnknownNon-melanocytic Skin Tumors | Melanocytic Skin TumorsAustria
-
National Taiwan University HospitalMinistry of Science and Technology, TaiwanUnknownSkin Cancer, Benign Skin Tumor, Inflammatory Skin DiseaseTaiwan
Clinical Trials on HM242
-
B. Braun Ltd. Centre of Excellence Infection ControlTerminated
-
B. Braun Ltd. Centre of Excellence Infection ControlRecruiting